Nath Bio-Genes (India) Limited (NATHBIOGEN)
Outcome of Board Meeting: Unaudited Financial results as of 30th June 2026.
Q1FY27 results:
Standalone:
Revenue 32.28bn +15.1% y-y (28.02bn)
EBITDA 3.41bn +14.7% y-y (2.97bn)
EBITDA margin 10.6% (10.6%) +0 bps y-y
PAT 3.27bn +11.8% y-y (2.92bn)
Consolidated:
Revenue 32.84bn +15.7% y-y (28.37bn)
EBITDA 3.60bn +19.8% y-y (3.01bn)
EBITDA margin 11.0% (10.6%) +40 bps y-y
PAT 3.23bn +14.1% y-y (2.83bn)
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 NATHBIOGEN — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add NATHBIOGEN to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Nath Bio-Genes (India) Limited
Important.
The summary above is generated automatically from Nath Bio-Genes (India) Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.